Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.37 |
| ▸ | PSMB11 | A5LHX3 | 5/20 | 0.36 |
| ▸ | PSMA7 | O14818 | 5/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.36 |
| ▸ | PSMA1 | P25786 | 5/20 | 0.36 |
| ▸ | PSMA2 | P25787 | 5/20 | 0.36 |
| ▸ | PSMA3 | P25788 | 5/20 | 0.36 |
| ▸ | PSMA4 | P25789 | 5/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 5/20 | 0.36 |
| ▸ | PSMA5 | P28066 | 5/20 | 0.36 |
| ▸ | PSMB4 | P28070 | 5/20 | 0.36 |
| ▸ | PSMB6 | P28072 | 5/20 | 0.36 |
| ▸ | PSMB10 | P40306 | 5/20 | 0.36 |
| ▸ | PSMB3 | P49720 | 5/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.36 |
| ▸ | PSMA6 | P60900 | 5/20 | 0.36 |
| ▸ | PSMA8 | Q8TAA3 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6463639 | 0.87 | PSMB5 (0.37) | POLBFPR2PSMB5PSMB11PSMA7 | |
| SCHEMBL7044868 | 0.85 | LMNA (0.37) | EPHX2 | |
| SCHEMBL6464160 | 0.80 | LMNA (0.39) | EPHX2 | |
| SCHEMBL7182965 | 0.78 | KMT2A (0.36) | EPHX2 | |
| SCHEMBL7043181 | 0.77 | POLB (0.39) | POLBFPR2BDKRB2ADRB2ADRB1 | |
| SCHEMBL7047004 | 0.76 | MAPT (0.34) | — | |
| SCHEMBL7045443 | 0.75 | MEN1 (0.45) | EPHX2 | |
| SCHEMBL6466282 | 0.74 | LMNA (0.39) | EPHX2 | |
| SCHEMBL7049029 | 0.73 | RAB9A (0.38) | POLBEPHX2 | |
| SCHEMBL7049306 | 0.72 | DAGLA (0.44) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | POLB 3957/4885FPR2 2099/4885PSMB5 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.